
==== Front
World J Clin Cases
WJCC
World Journal of Clinical Cases
2307-8960
Baishideng Publishing Group Inc

jWJCC.v12.i26.pg5908
10.12998/wjcc.v12.i26.5908
97245
Retrospective Study
Magnetic resonance imaging-based radiomics model for preoperative assessment of risk stratification in endometrial cancer
Wei ZY et al. Risk stratification model for endometrial cancer
Wei Zhi-Yao Department of Obstetrics and Gynecology, Seventh Medical Center of Chinese People’s Liberation Army General Hospital, Beijing 100700, China

Zhang Zhe Department of Obstetrics and Gynecology, Seventh Medical Center of Chinese People’s Liberation Army General Hospital, Beijing 100700, China

Zhao Dong-Li Department of Obstetrics and Gynecology, Seventh Medical Center of Chinese People’s Liberation Army General Hospital, Beijing 100700, China

Zhao Wen-Ming National Genomics Data Center and Chinese Academy of Sciences Key Laboratory of Genome Sciences and Information, Beijing Institute of Genomics, Chinese Academy of Sciences and China National Center for Bioinformation, Beijing 100700, China

Meng Yuan-Guang Department of Obstetrics and Gynecology, Seventh Medical Center of Chinese People’s Liberation Army General Hospital, Beijing 100700, China. meng6512@vip.sina.com

Author contributions: Wei ZY, Zhang Z, and Zhao DL contributed to methodology; Wei ZY contributed to writing the original draft and formal analysis; Meng YG contributed to writing, reviewing, and editing; Wei ZY and Zhao DL contributed to supervision; All authors contributed to data curation and conceptualization and read and approved the final manuscript.

Corresponding author: Yuan-Guang Meng, PhD, Chief Doctor, Surgeon, Department of Obstetrics and Gynecology, Seventh Medical Center of Chinese People’s Liberation Army General Hospital, No. 5 Nanmencang, Dongsishitiao, Dongcheng District, Beijing 100700, China. meng6512@vip.sina.com

16 9 2024
16 9 2024
12 26 59085921
26 5 2024
19 6 2024
3 7 2024
©The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved.
2024
https://creativecommons.org/licenses/by-nc/4.0/ This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial.
BACKGROUND

Preoperative risk stratification is significant for the management of endometrial cancer (EC) patients. Radiomics based on magnetic resonance imaging (MRI) in combination with clinical features may be useful to predict the risk grade of EC.

AIM

To construct machine learning models to predict preoperative risk stratification of patients with EC based on radiomics features extracted from MRI.

METHODS

The study comprised 112 EC patients. The participants were randomly separated into training and validation groups with a 7:3 ratio. Logistic regression analysis was applied to uncover independent clinical predictors. These predictors were then used to create a clinical nomogram. Extracted radiomics features from the T2-weighted imaging and diffusion weighted imaging sequences of MRI images, the Mann-Whitney U test, Pearson test, and least absolute shrinkage and selection operator analysis were employed to evaluate the relevant radiomic features, which were subsequently utilized to generate a radiomic signature. Seven machine learning strategies were used to construct radiomic models that relied on the screening features. The logistic regression method was used to construct a composite nomogram that incorporated both the radiomic signature and clinical independent risk indicators.

RESULTS

Having an accuracy of 0.82 along with an area under the curve (AUC) of 0.915 [95% confidence interval (CI): 0.806-0.986], the random forest method trained on radiomics characteristics performed better than expected. The predictive accuracy of radiomics prediction models surpassed that of both the clinical nomogram (AUC: 0.75, 95%CI: 0.611-0.899) and the combined nomogram (AUC: 0.869, 95%CI: 0.702-0.986) that integrated clinical parameters and radiomic signature.

CONCLUSION

The MRI-based radiomics model may be an effective tool for preoperative risk grade prediction in EC patients.

Endometrial cancer
Risk stratification
Radiomics
Machine learning
Nomogram
==== Body
pmc Core Tip: Our research focused on the utilization of clinical features and radiomics derived from magnetic resonance imaging (MRI) in order to predict the risk grade of endometrial cancer (EC). In our studies, we constructed a predictive model capable of predicting preoperative EC risk. The MRI-based radiomics model put forth in this research showed strong predictive ability and great potential value for assessing the level of EC risk. The integration of predictive models into clinical practice would greatly enhance the preoperative selection of customized therapy.

INTRODUCTION

Endometrial cancer (EC), characterized by the abnormal growth of cells in the lining of the uterus, is a prevalent gynecologic malignancy with a significant global health impact for females[1]. The early detection rate of EC is normally high, with approximately 80% of cases being diagnosed in stage I, with almost 95% 5-year survival rates[2]. However, if a disease has spread regionally or far away, the 5-year survival rate is substantially lower (68% and 17%, respectively)[3].

According to the European Society for Medical Oncology, the European Society for Radiotherapy and Oncology, and the European Society of Gynaecological Oncology Consensus Conference non-molecular risk classification of EC from 2020[4], patients who are at a heightened risk demonstrate the presence of at least one of the subsequent histologic characteristics: Deep infiltration into the myometrium (DMI); a tumor of high grade; a histological subtype that is non-endometrioid; lymph-vascular spaces invasion (LVSI); spread beyond the uterus; or involvement of lymph nodes.

Bilateral salpingo-oophorectomy and total abdominal hysterectomy are the standard treatments for low-risk EC. Although numerous clinical trials have sought to demonstrate the benefits of adjuvant therapy and lymphadenectomy (LA) for EC in its early stages, whether it truly meets the needs of patients remains controversial[5]. Approximately 7%-10% of patients undergoing lymph node dissection have postoperative lymphatic fistula, and roughly 23% of people are said to have lower extremity lymphedema on average[6]. According to the guidelines, individuals diagnosed with low-risk endometrioid carcinoma exhibit a diminished likelihood of lymph node involvement, hence LA is not advised for these patients. However, high-risk patients who had previously had partial surgery who needed LA to complete staging may be a good candidate for this procedure. For patients with intermediate-risk and high-risk endometrial carcinoma, surgical tumor debulking including enlarged lymph nodes and adjuvant treatment is recommended.

Therefore, we merged intermediate and high-risk groups as the high-risk group. Hence, identifying an effective approach for accurately evaluating risk stratification in EC cancer before treatment is crucial to ensure precise decision-making. Precise evaluation of the primary tumor, lymph nodes, and distant metastases is crucial for predicting the risk stratification of EC, particularly in the context of DMI.

Transvaginal ultrasonography is inferior to magnetic resonance imaging (MRI), which provides higher diagnostic performance[7,8]. Preoperative evaluation of EC staging using combined MRI T2-weighted imaging (T2WI) sequences is considered the best way for accurate assessment of DMI, particularly in cases where there is disappearance of the junctional zone (commonly seen in postmenopausal patients) and poor tumor-myometrial contrast[9]. Nevertheless, there is often an overestimation of the stage in instances where the tumor affects the uterine horns, when the tumor extends extensively into the uterine wall causing thinning of the myometrium, or in the event it occurs in a leiomyomatous uterus marked due to the varied signal strength observed in the myometrium[10,11].

The utilization of radiomics within clinical decision systems has witnessed a notable surge in recent years, leading to enhanced precision in the realms of diagnosis, prognosis, and prediction[12,13]. The primary objective of radiomics is transforming medical pictures into digital information that encompasses physiological and fundamental descriptive variables, such as contrast enhancement, diffusion properties, and tracer pickup. Additionally, it encompasses fundamental describing metrics, among which are dimension, form, intensity, and texture[14]. The application of radiomics is frequently observed in the field of oncology. According to reports, medical imaging characteristics were useful in differentiating across EC risk groups[15,16].

In the assessment of the predictive capacity of three risk stratification models for lymph node transfer in endometrioid EC, Korkmaz et al[17] found that the model that exhibited the highest performance attained an area under the curve (AUC) value of 0.780. Liu et al[18] concluded that the utilization of texture analysis exhibited promising prospects in its capacity to function as imaging indicators for evaluating preoperative risk. However, additional study is required to examine the evaluation of MRI-based radiomic analysis in conjunction with clinical factors for the purpose of preoperative risk stratification in patients with EC.

The objective of the present research was to inquire into the utilization of clinical features and radiomics derived from MRI in order to predict the risk grade of EC.

MATERIALS AND METHODS

Patients

The retrospective inquiry in question was exempt from the requirement of informed consent as it had obtained approval from the institutional review board. We reviewed 315 patients with EC that had postoperative pathological results between January 2018 and January 2020 in our hospital. Based on the following criteria, 112 cases were included in the study. Patients were first stratified according to the European Society of Gynaecological Oncology, the European Society for Medical Oncology, and the European Society of Pathology 2020 guidelines and then divided into two groups: Low-risk (including patients belonging to the low-risk class according to the 2020 guidelines classification); and high-risk (including intermediate, intermediate-high, and high-risk classes).

The inclusion criteria were: (1) Patients with pathologically confirmed EC who received an MRI exam 2 wk before surgery; and (2) Individuals who had not received any therapeutic interventions, including surgical procedures, biopsies, radiation therapy, chemotherapy, or hormone therapy, prior to their MRI. The exclusion criteria were: (1) Patients with missing clinical data; (2) Poor MRI image quality or significant artifacts that did not match the requirement of analysis; and (3) Lesions with a diameter of less than 5 mm. A random assignment method was used to allocate patients in a 7:3 ratio between the training group (n = 78) and the validation cohort (n = 34). The research flowchart is portrayed in Figure 1.

Figure 1 Technology roadmap for this research. A: Flow chart of patient enrollment; B: Workflow of radiomics analysis process. AUC: Area under the curve; DT: Decision tree; EC: Endometrial cancer; KNN: K-nearest neighbor; LDA: Linear discriminant analysis; LR: Logistic regression; MRI: Magnetic resonance imaging; MSE: Mean-square error; RF: Random forest; ROC: Receiver operating characteristic; ROI: Region of interest.

Data and images collection

Clinical and histopathological traits of all selected patients, such as age, histological grade and subtype, International Federation of Gynaecology and Obstetrics staging, body mass index, hypertension, hyperlipidemia, diabetes mellitus, menstruation, menopause status, fertility history, serum cancer antigen (CA) 125 level, serum CA19-9 level, and drinking and smoking history, were collected. These data were obtained through consultation of the medical record system. MRI pictures of all patients in digital imaging and communications in the medicine type were exported.

All MRI examinations were performed using 3.0 T system MRI scanners (Magnetom Aera; Siemens Healthcare, Germany). The standard scanning protocol comprised axial fast spin-echo (FSE) T1-weighted images, axial FSE T2WI, axial fat suppression FSE T2WI, and sagittal FSE T2WI. The b values utilized in diffusion weighted imaging (DWI) encompassed the values of 0 and 1000 s/mm2. In the study, uterus-sagittal position T2WI were acquired for lesion segmentation. Other imaging was used as a reference for lesion segmentation. Then, the radiomics features were extracted based on T2WI and DWI sequences. Table 1 displays the MRI parameters in detail.

Table 1 Magnetic resonance imaging scanning parameters

Sequence	TR/TE in ms	FOV in mm × mm	Matrix	Slice gap in mm	Slice thickness in mm	
Axial T1WI	500/8.6	310 × 310	224 × 320	1	6	
Axial T2WI	6200/95	310 × 310	307 × 384	1	6	
Axial (FS)-T2WI	4000/93	310 × 310	256 × 320	1	5	
Sagittal (FS)-T2WI	6000/86	240 × 240	205 × 256	1	6	
Axial DWI	5000/69	327 × 245	115 × 192	1	4	
DWI: Diffusion weighted imaging; FOV: Field of view; FS: Fat suppression; T1WI: T1-weighted images; T2WI: T2-weighted imaging; TE: Echo Time; TR: Repetition time.

Image segmentation and radiomic features extraction

The open-source software three-dimensional (3D) slicer (version 5.2.1), which may be accessed at https://www.slicer.org, was employed for the purpose of image segmentation. Segmentation was performed independently and manually by two experienced doctors who were unaware of the pathological result of the patient. The entire tumor was included in the 3D volume of interest (VOI), which the medical professionals defined, divided, and fused for a layer after layer screen. In the event of a disagreement, the two doctors talked it out until an agreement was reached.

The VOIs underwent resampling to a voxel size of 3 mm × 3 mm × 3 mm before extracting features to produce isotropic voxels; to ensure that the gray-level values of all photos were dispersed over the same range, image normalization was carried out. The VOI of each patient was utilized to extract radiomics features using the free and publicly accessible python program pyradiomics (https://pypi.org/project/pyradiomics/). The following categories were created from the extracted features: First-order features; two-dimensional features; gray-level cooccurrence matrix (GLCM); gray-level dependence matrix; gray-level size-zone matrix; gray-level run-length matrix; and neighboring gray tone difference matrix[19]. In total, 1037 radiomics characteristics were retrieved.

Radiomic feature picking and signature building

To mitigate interference across the feature dimensions, the features underwent standardization making use of the Z-score method, which involves deducting the average value and dividing by the standard deviation. Initially, to assess what features could individually separate the low-risk group from the high-risk group, we conducted the Mann-Whitney U test. Only features exhibiting a P value of 0.05 were retained. Subsequently, to eliminate highly correlated features, we removed the features with P > 0.9. The utilization of the least absolute shrinkage and selection operator (Lasso) in data analysis allows for the reduction of coefficients associated with variables that are not relevant to survival to zero while retaining features that have coefficients that are not equal to zero[20,21]. In this study, the Lasso method was employed to identify radiomics properties with the highest impact, and a 10-fold cross-validation approach was implemented within the training cohort. The minimum criteria (minimum lambda) were used to identify the ideal tuning parameter.

The radiomic signature (radscore) was calculated by adding up all of the filtered eigen values and multiplying the total by the appropriate coefficients. Radscore = β1X1 + β2X2 + …βnXn, with the radiomic signature denoted as radscore, βn was the coefficient, and Xn was the eigenvalue[22]. The assessment of the consistency between radscore in the training and testing sets was conducted by employing the Wilcoxon rank sum Mann-Whitney U test.

Model construction

By applying univariate and multivariate regression analysis, the clinical independent predictors were discovered. Applying the independent predictors, a clinical nomogram was then produced. To categorize the EC based on their radiomics features because we needed a model to solve a binary classification problem and we did not have a very large sample size, seven popular binary machine learning algorithms [logistic regression (LR), K-nearest neighbor (KNN), decision tree (DT), random forest (RF), gradient boosting (GB), eXtreme GB (XGBoost), and GBDT] with good explanations were used. A combined prediction multivariate logistic regression model was developed by including the radiomic signature (radscore) and clinically significant predictors that demonstrated statistical significance in a multivariate regression analysis.

Model performance and comparison and statistical analysis

The building of the ideal radiomics model was accomplished by employing a machine learning technique that demonstrated the maximum AUC value in the validation cohort[23]. AUCs of the models were compared via the Delong test[24]. The calibration was verified using calibration curves. The method of decision curve analysis was employed in order to assess and quantify the clinical value associated with each model[25].

Statistical tests suitable for the data type were employed to compare the baseline data between the training and validation cohorts. Specifically, the χ2 test or the Fisher exact test were used for categorical variables, while the continuous variables were assessed using either the two-sample t-test or the Mann-Whitney U test. Statistical significance was attributed to data sets with P values lower than 0.05. Statistical analyses were performed utilizing the statistical product and service solutions (version 26.0, international business machines corporation, https://www.ibm.com/spss), R software (version 3.5.1, https://www.r-project.org/), and Python (version 3.5.6, https://www.python.org/).

RESULTS

Demographic characteristics

A sample size of 112 individuals, aged between 31 years and 84 years (average age of 58.35 ± 11.75 years), was partitioned into two separate sections: Low-risk (n = 56) and high-risk (n = 56; including 42 intermediate risk cases and 14 high-risk cases). The participants were randomized to the training and validation subgroups in a random manner, following a 7:3 ratio. In the training subgroup, there were 39 patients classified as low-risk and an equal number of 39 patients classified as high-risk. Similarly, in the validation cohort, there were 17 patients classified as low-risk and an equal number of 17 patients classified as high-risk. The training and validation cohorts did not significantly differ in either clinical or histological characteristics. Table 2 displays the fundamental characteristics of the individuals.

Table 2 Characteristics of endometrial cancer patients in the training and validation cohorts

Characteristics	Training cohort	Validation cohort	P value	
Number	78	34		
Age in yr	58.04 ± 11.54	59.06 ± 12.04	0.367	
Histological grade1			0.465	
G1/G2	58	23		
G3	20	11		
Risk classes			1.000	
Low-risk	39	17		
High-risk	39	17		
Histological subtype1			0.018	
Endometrioid	66	22		
Serous	6	5		
Clear cell	4	4		
Carcinosarcoma	2	3		
FIGO staging			0.765	
I	50	21		
II	11	7		
III	9	4		
IV	8	2		
BMI				
> 24	44	19	0.959	
≤ 24	34	15		
Hypertension			0.812	
Positive	20	8		
Negative	58	26		
DM			0.605	
Positive	15	8		
Negative	63	26		
Hyperlipidemia			0.338	
Positive	5	4		
Negative	73	30		
Menstruation			0.395	
Regular	48	18		
Irregular	30	16		
Menopausal status				
Premenopausal	57	27	0.477	
Postmenopausal	21	7		
Fertility			0.669	
Fertility	69	31		
Nonfertility	9	3		
CA125			0.617	
< 35 U/mL	61	28		
≥ 35 U/mL	17	6		
CA19-9			0.631	
< 27 U/mL	67	28		
≥ 27 U/mL	11	6		
Family history of cancer			0.292	
Positive	10	7		
Negative	68	27		
Drinking history			0.915	
Positive	5	2		
Negative	73	32		
Smoking history			0.606	
Positive	4	1		
Negative	74	33		
1 Histological grade and subtype of endometrioid adenocarcinoma from surgical specimen.

Data are n or mean ± standard deviation. FIGO: The International Federation of Gynaecology and Obstetrics; BMI: Body mass index; CA125: Cancer antigen 125; CA19-9: Cancer antigen 19-9; DM: Diabetes mellitus.

Radiomic feature selection and radiomic signature construction

The 3D Slicer software was utilized to extract a total of 1037 quantitative imaging feature parameters for each patient. Following deredundancy processing, 788 features were kept, and 15 feature parameters were chosen using the Lasso dimensionality reduction approach (Figure 2). The radiomics score for each patient was computed via a linear equation using the following formula:

Figure 2 Least absolute shrinkage and selection operator regression model for screening the radiomics characteristics of the training group. A: Screening of the radiomics features was performed through least absolute shrinkage and selection operator (Lasso) regression. The cross validation for Lasso regression, where the parameter λ was adjusted to find the best function set, is shown. The vertical dotted line on the left panel represents the log(λ) corresponding to the optimal λ; B: Screening of the radiomics features was performed through Lasso regression. The coefficients of texture parameters changed with λ. The vertical line corresponds to the 10 features selected with non-zero Lasso cross-validation coefficients. MSE: Mean-square error.

Radscore = (0.085 × original_firstorder_Minimum) + (0.046 × original_glcm_ldmn) + [(-0.039) × log-sigma-4-4-mm-3D_firstorder_Energy] + [(-0.075) × log-sigma-4-4-mm-3D_firstorder_Maximum] + [(-0.133) × wavelet-LLH_firstorder_Median] + (0.072 × wavelet-LLH_firstorder_Skewness) + [(-0.057) × wavelet-LLH_glszm_LowGrayLevelZoneEmphasis] + [(-0.077) × wavelet-LHL_firstorder_Median] + (0.048 × wavelet-LHL_glcm_ClusterProminence) + (0.145 × wavelet-LHH_glcm_ClusterProminence) + (0.046 × wavelet-HHL_glcm_JointEnergy) + [(-0.088) × wavelet-HHH_glcm_MCC] + [(-0.075) × wavelet-LHH_gldm_LargeDependenceLowGrayLevelEmphasis] + [(-0.038) × wavelet-LLL_glrlm_LongRunHighGrayLevelEmphasis] + (0.046 × wavelet-LLL_glszm_LargeAreaLowGrayLevelEmphasis).

The study observed that the radscore exhibited greater values in the high-risk subgroup in comparison to the low-risk subgroup. Additionally, statistical analysis demonstrated that the radscore had a strong capability to differentiate between EC patients with low risk and those with high risk, as observed in both the training and validation cohorts. Low-risk EC patients had a radscore of 0.25 ± 0.20 in the training cohort compared to high-risk patient radscores of 0.75 ± 0.15 (P = 0.000); in the validation cohort, low-risk EC patients had a radscore of 0.24 ± 0.39 compared to high-risk patient radscores of 0.67 ± 0.21 (P = 0.000) (Figure 3).

Figure 3 Comparison of low-risk and high-risk endometrial cancer radscores. A: Training groups; B: Testing groups. 1: Low-risk endometrial cancer; 0: High-risk endometrial cancer.

Development and validation of the clinical model

Logistic regression analysis, both univariate and multivariate, was used to filter out all of the clinically suspicious risk factors (Table 3). The findings revealed that age, CA125, and CA19-9 were clinical independent predictors. A clinical model was constructed with the predictors. The AUC was 0.751 [95% confidence interval (CI): 0.611-0.899] in validation set, and accuracy was 0.706. Figure 4A depicts the clinical prediction model nomogram.

Figure 4 Nomogram to predict endometrial cancer risk. Cancer antigen (CA) 125 label 1 corresponds to serum levels below 35 U/mL, and label 0 corresponds to serum levels higher than 35 U/mL. CA19-9 label 1 corresponds to serum levels below 27 U/mL, and label 0 corresponds to serum levels higher than 27 U/mL. A: Nomogram developed by clinical predictors; B: Radiomics-clinical combined nomogram.

Table 3 Univariate regression analysis and multivariate regression analysis

Characteristics	Univariate regression OR (95%CI)	P value	Multivariate regression OR (95%CI)	P value	
Age	Reference 1.091 (1.038-1.147)	0.000	Reference 1.10 (1.000-1.019)	0.048	
BMI					
> 24	Reference				
≤ 24	2.333 (0.933-5.833)	0.070			
Hypertension					
Positive	Reference				
Negative	0.438 (0.152-1.256)	0.124			
Diabetes mellitus					
Positive	Reference				
Negative	0.848 (0.274-2.619)	0.774			
Hyperlipidemia					
Positive	Reference				
Negative	0.649 (0.102-4.113)	0.646			
Menstruation					
Regular	Reference				
Irregular	1.591 (0.615-4.114)	0.338			
Menopausal status					
Premenopausal	Reference				
Postmenopausal	2.560 (0.898-7.296)	0.079			
Reproductive history					
Positive	Reference				
Negative	0.777 (0.192-3.142)	0.724			
CA125					
< 35 U/mL	Reference		Reference		
≥ 35 U/mL	26.435 (3.284-29.776)	0.002	1.515 (1.163-1.973)	0.003	
CA19-9			Reference		
< 27 U/mL	Reference		1.355 (1.030-1.783)	0.033	
≥ 27 U/mL	5.550 (1.114-27.648)	0.036			
Family history of cancer					
Negative	Reference				
Positive	1.000 (0.265-3.772)	1.000			
Drinking history					
Negative	Reference				
Positive	4.343 (0.463-40.749)	0.199			
Smoke history					
Negative	Reference				
Positive	0.316 (0.031-3.177)	0.328			
Radscore	1.027 (1.002-1.054)	0.038	1.025 (0.990-1.060)	0.016	
BMI: Body mass index; CA125: Cancer antigen 125; CA19-9: Cancer antigen 19-9; CI: Confidence interval; OR: Odds ratio.

Development and validation of the radiomics models

Radiomics models were created using LR, KNN, DT, RF, GB, XGBoost, and GBDT. The model performance information is displayed in Table 4. The discrimination of the RF algorithm model outperformed the others.

Table 4 Outcomes of radiomics models in validation set

Algorithms	AUC (95%CI)	Accuracy	Sensitivity	Specificity	
LR	0.794 (0.706-0.976)	0.794	0.765	0.824	
KNN	0.893 (0.766-0.971)	0.765	0.823	0.705	
DT	0.676 (0.529-0.824)	0.676	0.529	0.824	
RF	0.915 (0.806-0.986)	0.824	0.824	0.824	
GB	0.907 (0.792-0.979)	0.794	0.706	0.882	
XGBoost	0.869 (0.739-0.965)	0.765	0.706	0.824	
GBDT	0.872 (0.742-0.958)	0.765	0.647	0.882	
AUC: Area under the curve; CI: Confidence interval; DT: Decision tree; GB: Gradient boosting; GBDT: Gradient boosting decision tree; KNN: K-nearest neighbor; LR: Logistic regression; RF: Random forest; XGBoost: eXtreme gradient boosting.

Development and validation of the combined model

The LR technique was employed to generate a nomogram that integrated the variables of age, CA125, CA19-9, and radscore into a combined model. The AUC in the test collection demonstrated outstanding discrimination, with a value of 0.869 (95%CI: 0.702-0.986). Figure 4B displays the nomogram representing the combined prediction models.

Comparison of models

Figure 5 including the receiver operating characteristic curves, calibration curves, and decision curve analysis, presents a comparative analysis of the performance between a clinical model, the best radiomics model, and the combined model. According to the Delong test (P < 0.05), the radiomics model exhibited superior discriminatory performance compared to both the clinical and combined models.

Figure 5 Evaluation of the radiomics model, clinical model, and combined model for predicating endometrial cancer risk grading. A: Receiver operating characteristic curve; B: Calibration curve; C: Decision curve analysis. AUC: Area under the curve.

DISCUSSION

This study involved the development of three models that were based on clinical independent risk factors, radiomics features, and the combination of clinical risk factors with radscore. The objective was to predict risk stratification for EC. This study demonstrated that the MRI-based radiomics models and the clinical models have good efficacy when assessing the risk grade of EC. The diagnostic efficacy of the combined model (AUC: 0.869, 95%CI: 0.702-0.986) was higher than the clinical model (AUC: 0.75, 95%CI: 0.611-0.899), and the radiomics model (AUC: 0.915, 95%CI: 0.806-0.986) developed based on the imaging features extracted from the T2WI and DWI sequence had the highest efficacy. The RF model performed best in this investigation out of various classifiers utilized to build the radiomics predictive model. This study showcased the efficacy of utilizing a comprehensive tumor radiomics-based analysis to evaluate the risk classification of EC before surgical intervention. The radiomics model may be clinically effective in the individualized surgical care of EC patients since radiomics may extract relevant data about high-risk indicators prior to surgery.

Some studies have explored preoperative prediction of EC risk stratification. Yan et al[26] found that variables for high-risk EC included metabolic syndrome, CA125, age, and tumor grade after curettage. Saarelainen et al[27] also concluded that CA125 paired with other serum indicators was superior to CA125 alone in predicting the recurrence of disease in EC patients. CA125 is a factor that relates to high-risk EC. In line with this, age, CA125, and CA19-9 were independent risk factors associated with EC risk stratification in this study.

Previous studies have noted that patients with EC, particularly those exhibiting unfavorable prognostic factors such as tumor recurrences, grade 3 tumors, DMI, lymph node metastasis, and extrauterine disease, utilize CA125 as a biomarker for tumor detection[28]. CA125 has been integrated into many pre-surgery prediction models, with varying levels of effectiveness. In clinical settings, the utilization of a threshold value of 35 U/mL for CA125 can prove to be a valuable diagnostic tool due to its high sensitivity. This is evidenced by the fact that a mere 1% of females who are in good health exhibit CA125 levels surpassing this cutoff point[29]. Therefore, this widely used cutoff was also used in this study.

Furthermore, there is research that has demonstrated notable correlations between International Federation of Gynaecology and Obstetrics staging and several other characteristics. These factors encompass inadequate histological classification, progressed clinical stage, existence of metastatic lymph nodes, and heightened blood CA19-9 levels[30]. Elderly females are more likely to have metabolic syndrome, have worse basic health status, and are more likely to develop high-risk EC. A study showed that reproductive history was a high-risk indicator for the emergence of EC[31]. In the current study, however, this conclusion was not found, suggesting that reproductive history may be more related to the incidence of EC instead of risk grade.

Previous studies have found a connection between the characteristics of tumor texture and diagnosis and grading[32,33]. Celli et al[34] found that the differentiation of low-risk EC from other risk categories, as well as the identification of the existence of LVSI, can be achieved with moderate to high accuracy by the utilization of MRI-based whole-tumor radiomics and radio-genomic investigations. Using MRI texture features, Ueno et al[35] established preliminary mathematical modelling that showed a correlation with DMI, LVSI, and high tumor grade. The AUC of the model in predicting high-risk EC was 0.83, but they did not perform the volumetric analysis. High-throughput parameters were extracted for the current investigation, and 15 statistically significant features were then found to create a radiomics model. The model performed well in identifying low-risk and high-risk EC; the sensitivity and specificity of the validation cohort were 82.4% and 82.4%, and the AUC was 0.915.

The GLCM feature characterizes the spatial arrangement of grey intensity in a two-dimensional manner by quantifying the probability of observing specific pixel pairs with particular grey values[36,37]. The chosen feature in this study comprised six GLCM features, indicating a close association between the distribution of texture and spatial heterogeneity within tumors and tumor differentiation. Moreover, alterations in the internal texture of tumors play a crucial role in determining tumor risk grading.

Among the seven machine learning algorithms we used to develop a radiomics model, the RF model performed best. It is based on DT analysis; the algorithm builds DTs by employing a random selection process to determine a subset of the samples and a subset of the features to be used for the split at each node. This greatly reduces the variance term in the diagnostic error. This is an advantage over bagging of the DTs[38]. In the area of biomedical research, the characteristics of RF make it the perfect material for creating diagnostic models.

Our study had some limitations. First, our model might have been overfitted because we only included 112 patients in this early investigation. Second, even though the MRI was performed according to a set protocol, the retrospective nature of the study could result in inhomogeneity un the imaging data. Although normalization was used in the picture analysis, image standardization and normalization techniques still require research. Third, we included only T2WI map images in our model, which may potentially enable missing significant data. To limit the potential of biases from only one sequence, future studies should use multiparametric techniques.

CONCLUSION

The MRI-based radiomics model put forth in this research showed strong predictive ability and great potential value for assessing the level of EC risk. The integration of predictive models into clinical practice would greatly enhance the preoperative selection of customized therapy.

ACKNOWLEDGEMENTS

The authors express their heartfelt thanks to the staff of the Department of Obstetrics and Gynecology of our hospital.

Data sharing statement

The datasets generated and analyzed during the current study are not publicly available but are available from the corresponding author on reasonable request.

Institutional review board statement: This study was performed in line with the principles of the Declaration of Helsinki. The Institutional Ethics Review Board approved this retrospective study and waived the requirement for written informed consent (No: 2022-403).

Informed consent statement: The retrospective inquiry in question was exempt from the requirement of informed consent as it had obtained approval from the institutional review board.

Conflict-of-interest statement: The authors declare that they have no competing interests.

Provenance and peer review: Unsolicited article; Externally peer reviewed.

Peer-review model: Single blind

Specialty type: Medicine, research and experimental

Country of origin: China

Peer-review report’s classification

Scientific Quality: Grade B

Novelty: Grade B

Creativity or Innovation: Grade B

Scientific Significance: Grade B

P-Reviewer: Kotelevets SM S-Editor: Fan M L-Editor: Filipodia P-Editor: Wang WB
==== Refs
1 Sung H Ferlay J Siegel RL Laversanne M Soerjomataram I Jemal A Bray F Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries CA Cancer J Clin 2021 71 209 249 33538338
2 Pintican R Bura V Zerunian M Smith J Addley H Freeman S Caruso D Laghi A Sala E Jimenez-Linan M MRI of the endometrium - from normal appearances to rare pathology Br J Radiol 2021 94 20201347 34233457
3 PDQ Adult Treatment Editorial Board Endometrial Cancer Treatment (PDQ®): Health Professional Version. 2024 Feb 8. In: PDQ Cancer Information Summaries [Internet]. Bethesda (MD): National Cancer Institute (US); 2002-
4 Gultekin M Guler OC Yuce Sari S Akkus Yildirim B Onal C Celik H Yuce K Ayhan A Arik Z Kose F Altundag O Zoto Mustafayev T Atalar B Bolukbasi Y Yildiz F Multi-institutional validation of the ESMO-ESGO-ESTRO consensus conference risk grouping in Turkish endometrial cancer patients treated with comprehensive surgical staging J Obstet Gynaecol 2021 41 414 420 32347768
5 Jang JW Lee LJ External Beam, Brachytherapy, or Chemotherapy? Defining Adjuvant Therapy for Early-Stage and High- and High-Intermediate-Risk Endometrial Cancer J Clin Oncol 2019 37 1778 1784 31163010
6 Yost KJ Cheville AL Al-Hilli MM Mariani A Barrette BA McGree ME Weaver AL Dowdy SC Lymphedema after surgery for endometrial cancer: prevalence, risk factors, and quality of life Obstet Gynecol 2014 124 307 315 25004343
7 Kinkel K Forstner R Danza FM Oleaga L Cunha TM Bergman A Barentsz JO Balleyguier C Brkljacic B Spencer JA European Society of Urogenital Imaging Staging of endometrial cancer with MRI: guidelines of the European Society of Urogenital Imaging Eur Radiol 2009 19 1565 1574 19194709
8 Sala E Crawford R Senior E Shaw A Simcock B Vrotsou K Palmer C Rajan P Joubert I Lomas D Added value of dynamic contrast-enhanced magnetic resonance imaging in predicting advanced stage disease in patients with endometrial carcinoma Int J Gynecol Cancer 2009 19 141 146 19258956
9 Wu LM Xu JR Gu HY Hua J Haacke EM Hu J Predictive value of T2-weighted imaging and contrast-enhanced MR imaging in assessing myometrial invasion in endometrial cancer: a pooled analysis of prospective studies Eur Radiol 2013 23 435 449 22865275
10 Haldorsen IS Husby JA Werner HM Magnussen IJ Rørvik J Helland H Trovik J Salvesen ØO Espeland A Salvesen HB Standard 1.5-T MRI of endometrial carcinomas: modest agreement between radiologists Eur Radiol 2012 22 1601 1611 22453859
11 Bi Q Chen Y Wu K Wang J Zhao Y Wang B Du J The Diagnostic Value of MRI for Preoperative Staging in Patients with Endometrial Cancer: A Meta-Analysis Acad Radiol 2020 27 960 968 31636004
12 Wang Q Li Q Mi R Ye H Zhang H Chen B Li Y Huang G Xia J Radiomics Nomogram Building From Multiparametric MRI to Predict Grade in Patients With Glioma: A Cohort Study J Magn Reson Imaging 2019 49 825 833 30260592
13 Manganaro L Nicolino GM Dolciami M Martorana F Stathis A Colombo I Rizzo S Radiomics in cervical and endometrial cancer Br J Radiol 2021 94 20201314 34233456
14 Lambin P Leijenaar RTH Deist TM Peerlings J de Jong EEC van Timmeren J Sanduleanu S Larue RTHM Even AJG Jochems A van Wijk Y Woodruff H van Soest J Lustberg T Roelofs E van Elmpt W Dekker A Mottaghy FM Wildberger JE Walsh S Radiomics: the bridge between medical imaging and personalized medicine Nat Rev Clin Oncol 2017 14 749 762 28975929
15 Bi WL Hosny A Schabath MB Giger ML Birkbak NJ Mehrtash A Allison T Arnaout O Abbosh C Dunn IF Mak RH Tamimi RM Tempany CM Swanton C Hoffmann U Schwartz LH Gillies RJ Huang RY Aerts HJWL Artificial intelligence in cancer imaging: Clinical challenges and applications CA Cancer J Clin 2019 69 127 157 30720861
16 Moro F Albanese M Boldrini L Chiappa V Lenkowicz J Bertolina F Mascilini F Moroni R Gambacorta MA Raspagliesi F Scambia G Testa AC Fanfani F Developing and validating ultrasound-based radiomics models for predicting high-risk endometrial cancer Ultrasound Obstet Gynecol 2022 60 256 268 34714568
17 Korkmaz V Meydanli MM Yalçın I Sarı ME Sahin H Kocaman E Haberal A Dursun P Güngör T Ayhan A Comparison of three different risk-stratification models for predicting lymph node involvement in endometrioid endometrial cancer clinically confined to the uterus J Gynecol Oncol 2017 28 e78 29027396
18 Liu Z Wang S Dong D Wei J Fang C Zhou X Sun K Li L Li B Wang M Tian J The Applications of Radiomics in Precision Diagnosis and Treatment of Oncology: Opportunities and Challenges Theranostics 2019 9 1303 1322 30867832
19 van Griethuysen JJM Fedorov A Parmar C Hosny A Aucoin N Narayan V Beets-Tan RGH Fillion-Robin JC Pieper S Aerts HJWL Computational Radiomics System to Decode the Radiographic Phenotype Cancer Res 2017 77 e104 e107 29092951
20 Sauerbrei W Royston P Binder H Selection of important variables and determination of functional form for continuous predictors in multivariable model building Stat Med 2007 26 5512 5528 18058845
21 Vasquez MM Hu C Roe DJ Chen Z Halonen M Guerra S Least absolute shrinkage and selection operator type methods for the identification of serum biomarkers of overweight and obesity: simulation and application BMC Med Res Methodol 2016 16 154 27842498
22 Huang Y Liu Z He L Chen X Pan D Ma Z Liang C Tian J Liang C Radiomics Signature: A Potential Biomarker for the Prediction of Disease-Free Survival in Early-Stage (I or II) Non-Small Cell Lung Cancer Radiology 2016 281 947 957 27347764
23 Rui W Qiao N Wu Y Zhang Y Aili A Zhang Z Ye H Wang Y Zhao Y Yao Z Radiomics analysis allows for precise prediction of silent corticotroph adenoma among non-functioning pituitary adenomas Eur Radiol 2022 32 1570 1578 34837512
24 DeLong ER DeLong DM Clarke-Pearson DL Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach Biometrics 1988 44 837 845 3203132
25 Steyerberg EW Vickers AJ Cook NR Gerds T Gonen M Obuchowski N Pencina MJ Kattan MW Assessing the performance of prediction models: a framework for traditional and novel measures Epidemiology 2010 21 128 138 20010215
26 Yan BC Li Y Ma FH Feng F Sun MH Lin GW Zhang GF Qiang JW Preoperative Assessment for High-Risk Endometrial Cancer by Developing an MRI- and Clinical-Based Radiomics Nomogram: A Multicenter Study J Magn Reson Imaging 2020 52 1872 1882 32681608
27 Saarelainen SK Peltonen N Lehtimäki T Perheentupa A Vuento MH Mäenpää JU Predictive value of serum human epididymis protein 4 and cancer antigen 125 concentrations in endometrial carcinoma Am J Obstet Gynecol 2013 209 142.e1 142.e6
28 Shawn LyBarger K Miller HA Frieboes HB CA125 as a predictor of endometrial cancer lymphovascular space invasion and lymph node metastasis for risk stratification in the preoperative setting Sci Rep 2022 12 19783 36396713
29 Bast RC Jr Klug TL St John E Jenison E Niloff JM Lazarus H Berkowitz RS Leavitt T Griffiths CT Parker L Zurawski VR Jr Knapp RC A radioimmunoassay using a monoclonal antibody to monitor the course of epithelial ovarian cancer N Engl J Med 1983 309 883 887 6310399
30 Bian J Sun X Li B Ming L Clinical Significance of Serum HE4, CA125, CA724, and CA19-9 in Patients With Endometrial Cancer Technol Cancer Res Treat 2017 16 435 439 27562869
31 Sponholtz TR Palmer JR Rosenberg L Hatch EE Adams-Campbell LL Wise LA Reproductive factors and incidence of endometrial cancer in U.S. black women Cancer Causes Control 2017 28 579 588 28361447
32 Xu X Li H Wang S Fang M Zhong L Fan W Dong D Tian J Zhao X Multiplanar MRI-Based Predictive Model for Preoperative Assessment of Lymph Node Metastasis in Endometrial Cancer Front Oncol 2019 9 1007 31649877
33 Chu H Pang P He J Zhang D Zhang M Qiu Y Li X Lei P Fan B Xu R Value of radiomics model based on enhanced computed tomography in risk grade prediction of gastrointestinal stromal tumors Sci Rep 2021 11 12009 34103619
34 Celli V Guerreri M Pernazza A Cuccu I Palaia I Tomao F Di Donato V Pricolo P Ercolani G Ciulla S Colombo N Leopizzi M Di Maio V Faiella E Santucci D Soda P Cordelli E Perniola G Gui B Rizzo S Della Rocca C Petralia G Catalano C Manganaro L MRI- and Histologic-Molecular-Based Radio-Genomics Nomogram for Preoperative Assessment of Risk Classes in Endometrial Cancer Cancers (Basel) 2022 14
35 Ueno Y Forghani B Forghani R Dohan A Zeng XZ Chamming's F Arseneau J Fu L Gilbert L Gallix B Reinhold C Endometrial Carcinoma: MR Imaging-based Texture Model for Preoperative Risk Stratification-A Preliminary Analysis Radiology 2017 284 748 757 28493790
36 Park HJ Park B Lee SS Radiomics and Deep Learning: Hepatic Applications Korean J Radiol 2020 21 387 401 32193887
37 Chu H Lin X He J Pang P Fan B Lei P Guo D Ye C Value of MRI Radiomics Based on Enhanced T1WI Images in Prediction of Meningiomas Grade Acad Radiol 2021 28 687 693 32418785
38 Breiman L Bagging predictors Mach Learn 1996 24 123 140
